| US5973115A (en)* | 1987-05-15 | 1999-10-26 | Amgen Inc. | Method for potentiating and inhibiting insulin-like growth factor activity |
| US5258287A (en)* | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
| WO1989009792A1 (en)* | 1988-04-12 | 1989-10-19 | Synergen, Inc. | Method for potentiating and inhibiting insulin-like growth factor activity |
| US5324820A (en)* | 1988-07-15 | 1994-06-28 | Central Sydney Area Health Service | Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex |
| JP3178714B2 (en)* | 1988-07-15 | 2001-06-25 | セントラル・シドニー・エリア・ヘルス・サービス | Acid labile subunit (ALS) of insulin-like growth factor (IGF) binding protein complex |
| US6465423B1 (en) | 1988-07-15 | 2002-10-15 | Central Sydney Area Health Service | Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex |
| GB8826451D0 (en)* | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
| JPH06503711A (en)* | 1990-08-28 | 1994-04-28 | カイロン コーポレイション | Novel insulin-like growth factor binding protein (IGFBP-4) |
| US5212074A (en)* | 1990-08-28 | 1993-05-18 | Chiron Corporation | Genetic material encoding new insulin-like growth factor binding protein igfbp-6 |
| EP0546110B1 (en)* | 1990-08-28 | 2001-11-14 | Chiron Corporation | New insulin-like growth factor binding protein igfbp-5 |
| US6326154B1 (en) | 1990-11-19 | 2001-12-04 | Genentech, Inc. | Ligand-mediated immunofunctional hormone binding protein assay method |
| US5210017A (en)* | 1990-11-19 | 1993-05-11 | Genentech, Inc. | Ligand-mediated immunofunctional hormone binding protein assay method |
| DE69233155T2 (en) | 1991-01-08 | 2004-06-03 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN |
| US5198340A (en)* | 1991-01-17 | 1993-03-30 | Genentech, Inc. | Assay for free igf-i, igf-ii, and gh levels in body fluids |
| US5187151A (en)* | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
| US6420172B1 (en) | 1992-04-20 | 2002-07-16 | Tib Company, Llc | Method for inducing tumor immunity |
| US5407913A (en)* | 1992-12-03 | 1995-04-18 | Celtrix Pharmaceuticals, Inc. | Method and composition for systemic treatment of tissue injury |
| JPH08509595A (en) | 1992-11-04 | 1996-10-15 | カイロン コーポレイション | Truncated insulin-like growth factor binding protein with mitogenic activity |
| US6124259A (en)* | 1993-01-28 | 2000-09-26 | Celtrix Pharmaceuticals, Inc. | Method for treating ophthalmic disorders with IGFBP |
| EP0708655A1 (en)* | 1993-04-07 | 1996-05-01 | Amgen Boulder Inc. | Methods of using insulin-like growth factor binding proteins |
| PT723453E (en)* | 1993-08-03 | 2000-07-31 | Celtrix Pharma | METHOD OF TREATMENT OF REPRODUCTIVE DISORDERS |
| NZ271488A (en) | 1994-07-12 | 1998-01-26 | Human Genome Sciences Inc | Connective tissue growth factor-2 (ctgf-2) |
| US7026299B2 (en) | 1994-07-12 | 2006-04-11 | Human Genome Sciences, Inc. | Connective tissue growth factor-2 |
| EP0800530A4 (en)* | 1994-07-20 | 1998-12-02 | Celtrix Pharma | Igf/igfbp complex for promoting bone formation and for regulating bone remodeling |
| US5747280A (en)* | 1995-06-05 | 1998-05-05 | Human Genome Sciences, Inc. | Human vascular IBP-like growth factor |
| US5994302A (en)* | 1994-12-09 | 1999-11-30 | Human Genome Sciences, Inc. | Human vascular IBP-like growth factor |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| JP3971108B2 (en) | 1999-01-06 | 2007-09-05 | ジェネンテック・インコーポレーテッド | Insulin-like growth factor (IGF) I mutants |
| CA2356257C (en) | 1999-01-06 | 2012-10-16 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| WO2001087323A2 (en) | 2000-05-16 | 2001-11-22 | Genentech, Inc. | Method for treating cartilage disorders |
| IL157705A0 (en) | 2001-03-14 | 2004-03-28 | Genentech Inc | Igf antagonist peptides |
| HUE027218T2 (en) | 2003-09-12 | 2016-10-28 | Ipsen Biopharmaceuticals Inc | Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency |
| EP1670822A2 (en) | 2003-10-03 | 2006-06-21 | Genentech, Inc. | Igf binding proteins |
| MX2020002744A (en) | 2017-09-11 | 2020-10-01 | Takeda Pharmaceuticals Co | Methods and compositions for treating chronic lung diseases. |
| US20230381285A1 (en) | 2020-10-19 | 2023-11-30 | Oak Hill Bio Ltd | Compositions suitable for use in neonates |
| KR20240136382A (en) | 2022-01-19 | 2024-09-13 | 오크 힐 바이오 리미티드 | Compositions and methods for reducing oxidation of IGF-1/IGFBP |
| WO2023242442A1 (en) | 2022-06-17 | 2023-12-21 | Oak Hill Bio Limited | Method of maturing/differentiating neurons and/or modulating the vagus nerve |
| WO2023242440A1 (en) | 2022-06-17 | 2023-12-21 | Oak Hill Bio Limited | Treament of lungs in infants |
| WO2023242439A1 (en) | 2022-06-17 | 2023-12-21 | Oak Hill Bio Limited | Vascular stabilisation (preterm infants) |
| WO2024170612A1 (en) | 2023-02-14 | 2024-08-22 | Oak Hill Bio Limited | Treatment of healing dysregulation in gi tissue |